Impairment by Mucosal Adjuvants and Cross-Reactivity with Variant Peptides of the Mucosal Immunity Induced by Injection of the Fusion Peptide PADRE-ELDKWA

Clinical and Diagnostic Laboratory Immunology

Volumn 10, Issue 6, 2003, Pages 1103-1108

  Decroix, Nipa ^a   Pamonsinlapatham, Perayot ^a   Quan, Cahn P ^a   Bouvet, Jean Pierre ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; CYTOSINE; EPITOPE; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CROSS REACTION; FEMALE; HAPLOTYPE; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; VIRUS TRANSMISSION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; ANTIGENS, VIRAL; CROSS REACTIONS; EPITOPES, T-LYMPHOCYTE; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; IMMUNOGLOBULIN A; MICE; MICE, INBRED BALB C; MUCOUS MEMBRANE; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; VACCINES;

EID: 0345257037     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.10.6.1103-1108.2003     Document Type: Article

References (35)

1. Alexander, J., M. F. Del Guercio, A. Maewal, L. Qiao, J. Fikes, R. W. Chesnut, J. Paulson, D. R. Bundle, S. DeFrees, and A. Sette. 2000. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J. Immunol. 164:1625-1633.
2. Baba, T. W., V. Liska, R. Hofmann-Lehmann, J. Vlasak, W. Xu, S. Ayehunie, L. A. Cavacini, M. R. Posner, H. Katinger, G. Stiegler, B. J. Bernacky, T. A. Rizvi, R. Schmidt, L. R. Hill, M. E. Keeling, Y. Lu, J. E. Wright, T. C. Chou, and R. M. Ruprecht. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:200-206.
3. + T cells. Immunology 105:204-242.
4. Belyakov, I. M., Z. Hel, B. Kelsall, V. A. Kuznetsov, J. D. Alhers, J. Nacsa, D. I. Watkins, T. M. Allen, A. Sette, J. Altman, R. Woodward, P. D. Markham, J. D. Clemens, G. Franchini, W. Strober, and J. A. Berzofsky. 2001. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med. 7:1320-1326.
5. Berneman, A., L. Bélec, V. A. Fischetti, and J. P. Bouvet. 1998. The specific patterns of human immunoglobulin G antibodies in serum differ from those in autologous secretions. Infect. Immun. 66:4163-4168.
6. Bouvet, J. P., N. Decroix, and P. Pamonsinlapatham. 2002. Stimulation of local antibody production: parenteral or mucosal vaccination? Trends Immunol. 23:209-213.
7. Brandtzaeg, P., I. N. Farstad, and G. Haraldsen. 1999. Regional specialization in the mucosal immune system: primed cells do not always home along the same tract. Immunol. Today 20:267-277.
8. Brandtzaeg, P., I. N. Farstad, F. E. Johansen, H. C. Morton, I. N. Norderhaug, and T. Yamanaka. 1999. The B-cell system of human mucosae and exocrine glands. Immunol. Rev. 67:45-87.
9. Burns, J. W., M. Siadat-Pajouh, A. A. Krishnaney, and H. B. Greenberg. 1996. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 272:104-107.
10. Conley, A. J., J. A. Kessler, L. J. Boots, P. M. McKenna, W. A. Schleif, E. A. Emini, G. E. Mark, H. Katinger, E. K. Cobb, S. M. Lunceford, S. R. Rouse, and K. K. Murthy. 1996. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J. Virol. 70:6751-6758.
11. Decroix, N., H. Hocini, C. P. Quan, B. Bellon, M. D. Kazatchkine, and J. P. Bouvet. 2001. Induction in mucosa of IgG and IgA antibodies against parenterally administered soluble immunogens. Scand. J. Immunol. 53:401-409.
12. Decroix, N., C. P. Quan, P. Pamonsinlapatham, and J. P. Bouvet. 2002. Mucosal immunity by intramuscular administration of free peptides in-line with PADRE: IgA antibodies to the ELDKWA epitope of HIV gp41. Scand. J. Immunol. 56:59-65.
13. Eriksson, K., and J. Holmgren. 2002. Recent advances in mucosal vaccines and adjuvants. Curr. Op. Immunol. 14:666-672.
14. Giffroy, D., A. Langendries, M. Maurice, F. Daniel, B. Lardreux, P. J. Courtoy, and J.-P. Vaerman. 1998. In vivo stimulation of polymeric Ig receptor transcytosis by circulating polymeric IgA in rat liver. Int. Immunol. 10:347-354.
15. Hanna, S. L., C. Yang, S. M. Owen, and R. B. Lal. 2002. Variability of critical epitopes within HIV-1 heptad repeat domains for selected entry inhibitors in HIV-infected populations worldwide. AIDS 16:1603-1608.
16. Horner, A. A., N. Cinman, A. Ronaghy, and E. Raz. 2000. Mucosal adjuvanticity of immunostimulatory DNA sequences. Springer Semin. Immunopathol. 22:133-146.
17. Kato, H., R. Kato, K. Fujihashi, and J. R. McGhee. 2001. Role of microbial antibodies in viral infections. Curr. Top. Microbiol. Immunol. 260:201-228.
18. Kraehenbuhl, J. P., and M. R. Neutra. 2000. Epithelial M cells: differentiation and function. Annu. Rev. Cell Dev. Biol. 16:301-332.
19. Mascola, J. R., G. Stiegler, T. C. VanCott, H. Katinger, C. B. Carpenter, C. E. Hanson, H. Beary, D. Hayes, S. S. Frankel, D. L. Birx, and M. G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
20. Mazanec, M. B., J. G. Nedrud, C. S. Kaetzel, and M. E. Lamm. 1993. A three-tiered view of the role of IgA in mucosal defense. Immunol. Today 14:430-435.
21. Moldoveanu, Z., M. W. Russell, H. Y. Wu, W. Q. Huang, R. W. Compans, and J. Mestecky. 1995. Compartmentalization within the common mucosal immune system. Adv. Exp. Med. Biol. 371A:97-101.
22. Mostov, K. E. 1994. Transepithelial transport of immunoglobulins. Annu. Rev. Immunol. 12:63-84.
23. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
24. Naficy, A. B., D. D. Trach, N. T. Ke, N. T. Chuc, A. Sorkin, N. R. Rao, T. H. Sy, V. D. Thiem, D. G. Cahn, R. T. Mahoney, J. Holmgren, B. Invanoff, and J. D. Clemens. 2001. Cost of immunization with a locally produced oral cholera vaccine in Viet Nam. Vaccine 19:3720-3725.
25. Pizza, M., M. M. Giuliani, M. R. Fontana, E. Monaci, G. Douce, G. Dougan, K. H. Mills, R. Rappuoli, and G. Del Giudice. 2001. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19:2534-2541.
26. Purtscher, M., A. Trkola, A. Grassauer, P. Schulz, A. Klima, S. Döpper, G. Gruber, A. Buchacher, T. Muster, and H. Katinger. 1996. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS 10:587-593.
27. Quan, C. P., A. Berneman, R. Pirčs, S. Avrameas, and J. P. Bouvet. 1997. Natural polyreactive secretory immunoglobulin A autoantibodies as a possible barrier to infection in humans. Infect. Immun. 65:3997-4004.
28. Rappuoli, R., M. Pizza, G. Douce, and G. Dougan. 1999. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today 20:493-500.
29. Roman, F., D. Gonzalez, C. Lambert, S. Deroo, A. Fischer, T. Baurith, T. Staub, R. Boulme, V. Arendt, F. Schneider, R. Hemmer, and J. C. Schmit. 2003. Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J. Acquir. Immune Defic. Syndr. 32:134-139.
30. Sabin, A. B., and L. R. Boulger. 1973. History of Sabin attenuated poliovirus oral live vaccine strains. J. Biol. Stand. 1:115-118.
31. Stokes, C. R., J. F. Southill, and M. W. Turner. 1975. Immune exclusion is a function of IgA. Nature 255:745-746.
32. Trkola, A., A. B. Pomales, H. Yuan, B. Korber, P. J. Maddon, G. P. Allaway, H. Katinger, C. F. I. Barbas, D. R. Burton, D. D. Ho, and J. P. Moore. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:6609-6617.
33. Vinavedra, M., H. Carol, J. Holmgren, and C. Czerkinsky. 1997. "PER-FEXT": a direct method for quantitative assessment of cytokine production in vivo at the local level. Res. Immunol. 148:257-266.
34. Wei, W. Z., S. Ratner, T. Shibuya, G. Yoo, and A. Jani. 2001. Foreign antigenic peptides delivered to the tumor as targets of cytotoxic T cells. J. Immunol. Methods 258:141-150.
35. Xiao, Y., X.-N. Dong, and Y.-H. Chen. 2000. Induction of high levels of antibodies recognizing the neutralizing epitope ELDKWA and the D- or K-position-mutated epitopes by candidate epitope vaccines against HIV-1. Int. Arch. Allergy Immunol. 122:287-292.